Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic, type 2 inflammatory disease that often remains uncontrolled despite standard medical and surgical treatment. According to the international EUFOREA definition, uncontrolled CRSwNP is defined by¹:

• 1. Patient-reported lack of control
• 2. Clinically relevant symptoms of active disease

Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.^1,2

As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.³

This Italian monocentric study (De Corso et al., 2022) evaluated the real-life effectiveness of dupilumab over the first year of treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (N=57).² The results from this real-life observational study reinforces the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and both the study design and results are consistent with the approved SmPC.^1,2,3